Sage Therapeutics, Inc. Expected to Earn Q1 2025 Earnings of ($1.62) Per Share (NASDAQ:SAGE)

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Sage Therapeutics in a research report issued on Friday, April 26th. HC Wainwright analyst D. Tsao anticipates that the biopharmaceutical company will post earnings of ($1.62) per share for the quarter. HC Wainwright has a “Neutral” rating and a $25.00 price objective on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.49) per share. HC Wainwright also issued estimates for Sage Therapeutics’ Q2 2025 earnings at ($1.59) EPS, Q3 2025 earnings at ($1.13) EPS and Q4 2025 earnings at ($1.15) EPS.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.17). Sage Therapeutics had a negative net margin of 552.52% and a negative return on equity of 56.81%. The firm had revenue of $7.90 million during the quarter, compared to the consensus estimate of $5.26 million. During the same quarter last year, the firm posted ($2.46) earnings per share. Sage Therapeutics’s revenue was up 139.4% compared to the same quarter last year.

A number of other research firms have also issued reports on SAGE. Truist Financial reduced their target price on shares of Sage Therapeutics from $22.00 to $18.00 and set a “hold” rating for the company in a research note on Friday. StockNews.com raised Sage Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Scotiabank dropped their price objective on shares of Sage Therapeutics from $34.00 to $19.00 and set a “sector outperform” rating on the stock in a research note on Thursday, April 18th. Oppenheimer decreased their price objective on shares of Sage Therapeutics from $25.00 to $17.00 and set a “market perform” rating for the company in a report on Thursday, April 18th. Finally, The Goldman Sachs Group dropped their price objective on Sage Therapeutics from $28.00 to $19.00 and set a “neutral” rating on the stock in a research note on Friday. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $37.72.

Sage Therapeutics Stock Up 3.6 %

Shares of NASDAQ SAGE opened at $14.18 on Monday. Sage Therapeutics has a 52-week low of $10.92 and a 52-week high of $59.99. The stock has a market capitalization of $853.38 million, a P/E ratio of -1.69 and a beta of 0.86. The firm’s 50-day moving average price is $18.38 and its two-hundred day moving average price is $20.61.

Hedge Funds Weigh In On Sage Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. lifted its stake in Sage Therapeutics by 66.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,554 shares of the biopharmaceutical company’s stock valued at $217,000 after purchasing an additional 4,617 shares during the last quarter. Pinnacle Associates Ltd. grew its stake in shares of Sage Therapeutics by 69.6% during the 1st quarter. Pinnacle Associates Ltd. now owns 285,917 shares of the biopharmaceutical company’s stock worth $5,358,000 after acquiring an additional 117,344 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of Sage Therapeutics by 1,058.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 156,593 shares of the biopharmaceutical company’s stock valued at $2,935,000 after buying an additional 143,075 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its stake in Sage Therapeutics by 8.2% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 66,567 shares of the biopharmaceutical company’s stock worth $1,247,000 after purchasing an additional 5,068 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in Sage Therapeutics by 1,049.2% in the 4th quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 201,107 shares of the biopharmaceutical company’s stock valued at $4,358,000 after purchasing an additional 183,607 shares during the period. 99.22% of the stock is owned by hedge funds and other institutional investors.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.